ArticlePloS one2025
Contribution of xpert MTB/RIF assay and Urine LF-LAM for the diagnosis of tuberculosis in children aged 5 - 14 years, at selected health facilities in Ethiopia, 2016 - 2019.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundChildhood tuberculosis (TB) remains under-reported and undiagnosed. A full complement of diagnostic tests is oftentimes unavailable in resource limited country like Ethiopia. This study assesses the contribution of Xpert MTB/RIF assay and urine LF-LAM for childhood TB diagnosis using sputum and urine samples.
methodA facility based cross-sectional study was conducted in children between 5 and 14 years of age. Sputum and urine samples were collected from children with presumptive TB. The samples were tested for TB using LF-LAM, Xpert MTB/RIF assay, concentrated smear microscopy, and culture. Diagnostic performance of Xpert MTB/RIF assay was analyzed and compared against culture, which was used as the gold standard. Urine LF-LAM test result was compared to a composite reference standard.
resultOf 576 participants with presumptive TB enrolled in the study, 519 (90.1%) had complete clinical data and bacteriological laboratory test results. Active TB was diagnosed in 14.1% (73/519), and bacteriological confirmation was made in 10.1% (52/515) of children with presumptive TB. The odds of being diagnosed with a bacteriologically confirmed TB are significantly higher in children who have household contact history with TB patient (aOR 2.27, P = 0.03) and age above 10 years (aOR 3.67, P < 0.001). Xpert MTB/RIF test had sensitivity of 79% using culture as the gold standard. Compared to smear microscopy, the sensitivity of the Xpert MTB/RIF assay increased by 50% for children aged 5-9 years and by 40% for children and adolescents living with HIV (C/ALHIV). All bacteriologically confirmed (n = 2) and clinically diagnosed TB children (n = 2) who live with HIV were tested positive for urine LF-LAM. The overall sensitivity of urine LF-LAM was 27.6% when using the composite reference standard, compared to 17.9% when the bacteriological reference standard was applied.
conclusionsPulmonary TB diagnosis was greatly improved with the use of Xpert MTB/RIF assay, particularly in children aged 5-9 years and C/ALHIV who typically have difficulty producing good quality sputum. Urine LF-LAM performed well in children/adolescents who tested positive for HIV, but it performed poorly in the other variables, which suggests that urine LF-LAM testing did not play a critical role in TB diagnosis in children with negative HIV status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.